BLAINJECTIONINJECTABLE
Approved
Sep 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
STELARA (ustekinumab) by Johnson & Johnson is interleukin-12 antagonists [moa]. Approved for interleukin-12 antagonist [epc]. First approved in 2016.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STELARA (ustekinumab) is a monoclonal antibody that antagonizes interleukin-12, a key cytokine driving inflammatory and autoimmune responses. It is approved for treatment of psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The drug works by blocking IL-12 signaling, thereby suppressing pathogenic immune responses in these conditions.
Peak
Product is at peak commercial maturity; expect stable but not expanding team sizes as focus shifts to defending market share against biosimilars.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
Started Feb 2026
10 enrolled
Cancer
A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
Started Feb 2026
200 enrolled
Psoriasis
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
Started Jan 2026
200 enrolled
Inflammatory Bowel Disease (IBD)Crohn Disease (CD)Ulcerative Colitis (UC)+1 more
De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis
Started Oct 2025
115 enrolled
Crohn Disease (CD)Ulcerative Colitis (UC)
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Started Sep 2025
3,040 enrolled
Plaque Psoriasis
Worked on STELARA at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.